{"pmid":32467086,"title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","text":["Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","Clin Immunol","Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume","32467086"],"journal":"Clin Immunol","authors":["Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467086","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.clim.2020.108464","e_drugs":["Sirolimus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167109985697792,"score":9.490897,"similar":[{"pmid":32405269,"pmcid":"PMC7217787","title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","text":["Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.","Clin Immunol","Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume","32405269"],"journal":"Clin Immunol","authors":["Omarjee, Loukman","Janin, Anne","Perrot, Frederique","Laviolle, Bruno","Meilhac, Olivier","Mahe, Guillaume"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405269","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.clim.2020.108464","keywords":["cd, cluster of differentiation","covid-19, corona-virus-disease-2019","ctla-4, cytotoxic t lymphocyte associated protein 4","g-csf, granulocyte colony stimulating factor","ifn-gamma, interferon gamma","il, interleukin","ip-10, interferon gamma-induced protein 10","mcp-1, monocyte chemoattractant protein 1","mip-1alpha, macrophage inflammatory protein 1 alpha","nf-kappab, nuclear factor-kappa b","nlrp3, nucleotide-binding oligomerization domain (nod)-like receptor family, pyrin domain containing 3","pd-1, programmed cell death 1","ros, reactive oxygen species","sars-cov-2, severe acute respiratory syndrome coronavirus 2","tigit, t-cell immunoreceptor with ig and itim (immunoreceptor tyrosine-based inhibition motif) domains","tlr, toll like receptor","tnfalpha, tumor necrosis factor alpha","tim-3, t-cell immunoglobulin mucin-3","mtor, mammalian target of rapamycin"],"e_drugs":["Sirolimus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845466230785,"score":133.43375},{"pmid":32334502,"title":"The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","text":["The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge.","Curr Neurovasc Res","Maiese, Kenneth","32334502"],"abstract":["Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge."],"journal":"Curr Neurovasc Res","authors":["Maiese, Kenneth"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334502","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.2174/1567202617666200425205122","keywords":["amp activated protein kinase (ampk)","akt","covid-19","sars-cov-2","angiotensin converting enzyme 2","apoptosis","autophagy","coronaviruses","cytokines","diabetes mellitus","inflammation","influenza","interferons","interleukins","mtor complex 1 (mtorc1)","mtor complex 2 (mtorc2)","macrophage inflammatory protein 1-alpha (mip-1alpha)","mechanistic target of rapamycin (mtor)","metformin","monocyte chemoattractant protein 1 (mcp-1)","oxidative stress","tumor necrosis factor-alpha","virion"],"locations":["Rapamycin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494085365762,"score":60.171555},{"pmid":32376400,"title":"Cytokine storm syndrome in severe COVID-19.","text":["Cytokine storm syndrome in severe COVID-19.","Autoimmun Rev","Ruscitti, Piero","Berardicurti, Onorina","Iagnocco, Annamaria","Giacomelli, Roberto","32376400"],"journal":"Autoimmun Rev","authors":["Ruscitti, Piero","Berardicurti, Onorina","Iagnocco, Annamaria","Giacomelli, Roberto"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376400","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102562","locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097403580416,"score":54.346157},{"pmid":32339387,"title":"COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.","text":["COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.","Biofactors","Theoharides, Theoharis C","32339387"],"journal":"Biofactors","authors":["Theoharides, Theoharis C"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339387","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/biof.1633","locations":["pulmonary mast","luteolin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494180786178,"score":52.009285},{"pmid":32352407,"title":"Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","text":["Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.","J Clin Invest","Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan","32352407"],"abstract":["Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases."],"journal":"J Clin Invest","authors":["Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352407","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1172/JCI139642","e_drugs":["Catecholamines"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495698075648,"score":48.64731}]}